The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.
Publication
, Journal Article
Raghav, K; Strickler, JH
Published in: JAMA Oncol
October 1, 2019
Duke Scholars
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
October 1, 2019
Volume
5
Issue
10
Start / End Page
1511 / 1512
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Raghav, K., & Strickler, J. H. (2019). The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol, 5(10), 1511–1512. https://doi.org/10.1001/jamaoncol.2019.2985
Raghav, Kanwal, and John H. Strickler. “The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.” JAMA Oncol 5, no. 10 (October 1, 2019): 1511–12. https://doi.org/10.1001/jamaoncol.2019.2985.
Raghav K, Strickler JH. The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol. 2019 Oct 1;5(10):1511–2.
Raghav, Kanwal, and John H. Strickler. “The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.” JAMA Oncol, vol. 5, no. 10, Oct. 2019, pp. 1511–12. Pubmed, doi:10.1001/jamaoncol.2019.2985.
Raghav K, Strickler JH. The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol. 2019 Oct 1;5(10):1511–1512.
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
October 1, 2019
Volume
5
Issue
10
Start / End Page
1511 / 1512
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis